Primary Cells Market Size Share Competitive Landscape And Trend Analysis Report Report
RA01837
Primary Cells Market Size, Share, Competitive Landscape, and Trend Analysis Report by Origin, Type, End User, and Region: Global Opportunity Analysis and Industry Forecast, 2024-2033
The primary cells market was valued at $1,802.00 million in 2023 and is estimated to reach $5,327.60 million by 2033, exhibiting a CAGR of 11.5% from 2024 to 2033
Market Introduction and Definition
Primary cells are cells that are directly isolated from living tissues and maintained in vitro for the first time. Unlike immortalized cell lines that can proliferate indefinitely, primary cells have a finite lifespan, undergoing a limited number of cell divisions before they enter senescence and cease to divide. This finite lifespan is a crucial characteristic, as it means primary cells more accurately represent the physiological state of cells within an organism, retaining many of their original characteristics and functions.
The process of obtaining primary cells typically involves the mechanical or enzymatic disaggregation of tissues, followed by the isolation and culture of the desired cell type. This can be done using various techniques such as enzymatic digestion with trypsin or collagenase, or mechanical methods like mincing the tissue. Once isolated, primary cells are cultured in a controlled environment that mimics their natural conditions as closely as possible, including specific growth factors, nutrients, and extracellular matrix components.
Key Takeaways
- The primary cells market study covers 20 countries. The research includes a segment analysis of each country in terms of value ($million) for the projected period from 2024 to 2033.
- More than 1,500 product literatures, industry releases, annual reports, and other such documents of major energy storage system industry participants along with authentic industry journals, trade associations' releases, and government websites have been reviewed for generating high-value industry insights.
- The study integrates high-quality data, professional opinions and analysis, and critical independent perspectives. The research approach intends to provide a balanced view of global markets and assist stakeholders in making informed decisions in order to achieve their most ambitious growth objectives.
Industry Trends
- In October 2023, Kuraray Co., Ltd. launched PVA hydrogel microcarriers designed for cell cultures in regenerative medicine. The product is scheduled to debut globally in 2024, starting with the U.S., followed by Japan.
- In February 2022, CellulaREvolution obtained $2.2 million funding aimed at accelerating the rollout of their Continuous Cell Culture Technology.
- In March 2021, Axol Bioscience Ltd., revealed its merger with Censo Biotechnologies. The merger is intended to expand their range of services and products in iPSC-based immune cell, cardiac modeling, and neuroscience, catering to the drug discovery and screening sectors.
- In May 2020, BioIVT (U.S.) broadened its range of hepatic human primary cells by introducing high-purity Kupffer cells. This addition is intended to boost support for drug development and discovery efforts related to liver disorders. The introduction of high-purity Kupffer cells offers researchers a valuable resource for investigating and developing treatments for liver-related conditions.
Key Market Dynamics
The increasing demand for personalized medicine aims to tailor treatments to individual patients based on their unique genetic, environmental, and lifestyle factors. Primary cells, which are directly derived from patient tissues, offer a more accurate and relevant model for studying disease mechanisms and drug responses. Using a patient's own cells for drug testing and treatment planning enhances predictive accuracy. This is crucial for determining the efficacy and safety of treatments, minimizing adverse reactions, and optimizing therapeutic outcomes. Primary cells are invaluable in research applications such as drug discovery, toxicology studies, and regenerative medicine. According to the NIH, the Precision Medicine Initiative Cohort Program (All of Us Research Program) aims to enroll one million or more U.S. participants to improve health outcomes through tailored treatment strategies. They provide a more physiologically relevant context compared to immortalized cell lines, leading to more reliable data and insights. These factors are predicted to drive the primary cells market growth during the forecast period.
Primary cells are often more expensive to procure and maintain compared to cell lines. This cost includes sourcing tissues, processing, quality control, and storage. Obtaining primary cells typically involves sourcing tissues from living organisms, which requires ethical considerations, specialized facilities, and sometimes, specific donor criteria. This process can be costly due to the need for appropriate tissue procurement protocols and compliance with ethical guidelines. After obtaining tissues, primary cells need to be isolated and purified using complex and often labor-intensive methods. This process requires specialized equipment, reagents, and expertise, adding to the overall cost. These factors are anticipated to restrain the primary cells market growth during the forecast period.
The use of primary cells derived from patients allows for the creation of more accurate and personalized treatment plans. This approach is particularly valuable in fields such as oncology, where treatments can be tailored to the specific characteristics of a patient’s tumor cells. Patient-derived cells provide a more reliable model for drug testing and development, ensuring that new treatments are more effective and have fewer side effects. Primary cells from patients can be used to develop personalized cancer therapies. This can involve testing the efficacy of various drugs on the patient’s own cells before administering the treatment. The integration of genomic data with primary cell research can lead to precision medicine approaches, providing treatments based on individual genetic profiles. Primary cells are crucial in developing cell-based therapies for regenerative medicine. These therapies can replace or repair damaged tissues and organs, offering potential cures for various chronic diseases. Primary cells are used in tissue engineering to create bioengineered tissues and organs, which can be used for transplantation or disease modeling. These factors are anticipated to create opportunities in the primary cells market during the forecast years.
Acts and Initiatives in the Global Primary Cells Market
The market is experiencing rapid growth and transformation, driven by factors such as technological advancements, increasing healthcare costs, aging population, and rising demand for efficient and accessible healthcare services. The global primary cells market is influenced due to various aspects such as research funding, regulatory frameworks, and market accessibility.
- Governments often allocate substantial funds to support R&D in biotechnology and healthcare, including primary cells. For instance, in the U.S., the National Institutes of Health (NIH) and the National Science Foundation (NSF) provide grants and funding opportunities for research involving primary cells. As of 2023, NIH's annual budget allocation for biological research including primary cells was approximately $42 billion.
- Government agencies such as the FDA in the U.S. and the EMA (European Medicines Agency) in Europe regulate the use of primary cells in pharmaceutical and biotechnology applications. These regulations ensure safety, efficacy, and ethical standards in research and commercialization. For example, the FDA's guidelines on cell and gene therapy provide a framework for developers using primary cells in therapeutic applications.
Market Segmentation
The primary cells market is segmented into origin, type, end user, and region. On the basis of origin, the market is divided into human primary cells and animal primary cells. On the basis of type, the market is classified into hematopoietic cells, dermatocytes, gastrointestinal cells, hepatocytes, lung cells, renal cells, heart cells, musculoskeletal cells, and others. On the basis of end user, the market is divided into pharmaceutical & biotechnology companies and CROs, academic & research institutes, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Regional Market Outlook
The increasing healthcare expenditure in North America supports the demand for primary cells used in research, diagnostics, and therapeutic applications. Continuous advancements in technology are driving innovation in primary cell research and applications. This includes improved cell culture techniques, better preservation methods, and enhanced characterization tools. There is a significant investment in biomedical R&D across North America. This includes academic research institutions, pharmaceutical companies, and biotechnology firms focusing on cell biology and related fields. Primary cells are crucial for drug screening, toxicity testing, and disease modeling in pharmaceutical research. The demand for more physiologically relevant models to predict human responses is increasing, thereby boosting the demand for primary cells.
In October 2023, STEMCELL Technologies strengthened its footprint in Toronto with the inauguration of a new sales office. This strategic move is expected to enhance the company's visibility in Toronto and amplify its impact across North America.
Competitive Landscape
The major players operating in the primary cells market include Thermo Fisher Scientific, Merck KGaA, Lonza, Cell Biologics, PromoCell, ZenBio, STEMCELL Technologies, AllCells, American Type Culture Collection, Axol Biosciences, and others.
Recent Key Strategies and Developments
- In October 2020, iBio, Inc., a U.S.-based biotechnology firm, and Safi Biosolutions, Inc. revealed a strategic partnership aimed at developing growth factors and cytokines using iBio's FastPharming System.
- In June 2018, Lonza launched a new series of primary cells, featuring Kupffer cells, liver-derived endothelial cells, and hepatic stellate cells.
Key Sources Referred
- Food and Drug Administration (FDA)
- Clinical and Laboratory Standards Institute (CLSI)
- Centers for Disease Control and Prevention (CDC)
- World Health Organization (WHO)
- American Association for Clinical Chemistry (AACC)
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the primary cells market segments, current trends, estimations, and dynamics of the primary cells market analysis from 2023 to 2033 to identify the prevailing primary cells market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the primary cells market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global primary cells market statistics.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
Apart from the points mentioned above, the report includes the analysis of the regional as well as global primary cells market trends, key players, market segments, application areas, and market growth strategies.
| Aspect | Particulars |
| Historical Market Estimations | 2021-2022 |
| Base Year for Market Estimation | 2023 |
| Forecast Timeline for Market Projection | 2024-2033 |
| Geographical Scope | North America, Europe, Asia-Pacific, and LAMEA |
| Segmentation by Origin |
|
| Segmentation by Type |
|
| Segmentation by End User |
|
| Key Companies Profiled |
|
-
1. RESEARCH METHODOLOGY
1.1. Desk Research
1.2. Real time insights and validation
1.3. Forecast model
1.4. Assumptions and forecast parameters
1.5. Market size estimation
1.5.1. Top-down approach
1.5.2. Bottom-up approach
-
2. REPORT SCOPE
2.1. Market definition
2.2. Key objectives of the study
2.3. Report overview
2.4. Market segmentation
2.5. Overview of the impact of COVID-19 on Global Primary Cells Market
-
3. EXECUTIVE SUMMARY
-
4. MARKET OVERVIEW
4.1. Introduction
4.2. Growth impact forces
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Market value chain analysis
4.3.1. List of raw material suppliers
4.3.2. List of manufacturers
4.3.3. List of distributors
4.4. Innovation & sustainability matrices
4.4.1. Technology matrix
4.4.2. Regulatory matrix
4.5. Porter’s five forces analysis
4.5.1. Bargaining power of suppliers
4.5.2. Bargaining power of consumers
4.5.3. Threat of substitutes
4.5.4. Threat of new entrants
4.5.5. Competitive rivalry intensity
4.6. PESTLE analysis
4.6.1. Political
4.6.2. Economical
4.6.3. Social
4.6.4. Technological
4.6.5. Environmental
4.7. Impact of COVID-19 on Primary Cells Market
4.7.1. Pre-covid market scenario
4.7.2. Post-covid market scenario
-
5. Primary Cells Market, By Application
5.1. Overview
5.2 Hematopoietic Cells
5.2.1 Definition, key trends, growth factors, and opportunities
5.2.2 Market size analysis, by region, 2020-2027
5.2.3 Market share analysis, by country, 2020-2027
5.3 Dermatocytes
5.3.1 Definition, key trends, growth factors, and opportunities
5.3.2 Market size analysis, by region, 2020-2027
5.3.3 Market share analysis, by country, 2020-2027
5.4 Gastrointestinal Cells
5.4.1 Definition, key trends, growth factors, and opportunities
5.4.2 Market size analysis, by region, 2020-2027
5.4.3 Market share analysis, by country, 2020-2027
5.5 Hepatocytes
5.5.1 Definition, key trends, growth factors, and opportunities
5.5.2 Market size analysis, by region, 2020-2027
5.5.3 Market share analysis, by country, 2020-2027
5.6 Lung Cells
5.6.1 Definition, key trends, growth factors, and opportunities
5.6.2 Market size analysis, by region, 2020-2027
5.6.3 Market share analysis, by country, 2020-2027
5.7 Renal Cells
5.7.1 Definition, key trends, growth factors, and opportunities
5.7.2 Market size analysis, by region, 2020-2027
5.7.3 Market share analysis, by country, 2020-2027
5.8 Heart Cells
5.8.1 Definition, key trends, growth factors, and opportunities
5.8.2 Market size analysis, by region, 2020-2027
5.8.3 Market share analysis, by country, 2020-2027
5.9 Musculoskeletal Cells
5.9.1 Definition, key trends, growth factors, and opportunities
5.9.2 Market size analysis, by region, 2020-2027
5.9.3 Market share analysis, by country, 2020-2027
5.10 Other Primary Cells
5.10.1 Definition, key trends, growth factors, and opportunities
5.10.2 Market size analysis, by region, 2020-2027
5.10.3 Market share analysis, by country, 2020-2027
5.11 Research Dive Exclusive Insights
5.11.1 Market attractiveness
5.11.2 Competition heatmap
-
6. Primary Cells Market, By Distribution Channel
6.1. Overview
6.2 Life Science Research Companies
6.2.1 Definition, key trends, growth factors, and opportunities
6.2.2 Market size analysis, by region, 2020-2027
6.2.3 Market share analysis, by country, 2020-2027
6.3 Research Institutes
6.3.1 Definition, key trends, growth factors, and opportunities
6.3.2 Market size analysis, by region, 2020-2027
6.3.3 Market share analysis, by country, 2020-2027
6.4 Research Dive Exclusive Insights
6.4.1 Market attractiveness
6.4.2 Competition heatmap
-
7. Primary Cells Market, By Formula Type
7.1. Overview
7.2 Human Primary Cells
7.2.1 Definition, key trends, growth factors, and opportunities
7.2.2 Market size analysis, by region, 2020-2027
7.2.3 Market share analysis, by country, 2020-2027
7.3 Animal Primary Cells
7.3.1 Definition, key trends, growth factors, and opportunities
7.3.2 Market size analysis, by region, 2020-2027
7.3.3 Market share analysis, by country, 2020-2027
7.4 Research Dive Exclusive Insights
7.4.1 Market attractiveness
7.4.2 Competition heatmap
8. Primary Cells Market, By Region
8.1 North America
8.1.1 U.S
8.1.1.1 Market size analysis, By Application, 2020-2027
8.1.1.2 Market size analysis, By Distribution Channel, 2020-2027
8.1.1.3 Market size analysis, By Formula Type, 2020-2027
8.1.2 Canada
8.1.2.1 Market size analysis, By Application, 2020-2027
8.1.2.2 Market size analysis, By Distribution Channel, 2020-2027
8.1.2.3 Market size analysis, By Formula Type, 2020-2027
8.1.3 Mexico
8.1.3.1 Market size analysis, By Application, 2020-2027
8.1.3.2 Market size analysis, By Distribution Channel, 2020-2027
8.1.3.3 Market size analysis, By Formula Type, 2020-2027
8.1.4 Research Dive Exclusive Insights
8.1.4.1 Market attractiveness
8.1.4.2 Competition heatmap
8.2 Europe
8.2.1 Germany
8.2.1.1 Market size analysis, By Application, 2020-2027
8.2.1.2 Market size analysis, By Distribution Channel, 2020-2027
8.2.1.3 Market size analysis, By Formula Type, 2020-2027
8.2.2 UK
8.2.2.1 Market size analysis, By Application, 2020-2027
8.2.2.2 Market size analysis, By Distribution Channel, 2020-2027
8.2.2.3 Market size analysis, By Formula Type, 2020-2027
8.2.3 France
8.2.3.1 Market size analysis, By Application, 2020-2027
8.2.3.2 Market size analysis, By Distribution Channel, 2020-2027
8.2.3.3 Market size analysis, By Formula Type, 2020-2027
8.2.4 Spain
8.2.4.1 Market size analysis, By Application, 2020-2027
8.2.4.2 Market size analysis, By Distribution Channel, 2020-2027
8.2.4.3 Market size analysis, By Formula Type, 2020-2027
8.2.5 Italy
8.2.5.1 Market size analysis, By Application, 2020-2027
8.2.5.2 Market size analysis, By Distribution Channel, 2020-2027
8.2.5.3 Market size analysis, By Formula Type, 2020-2027
8.2.6 Rest of Europe
8.2.6.1 Market size analysis, By Application, 2020-2027
8.2.6.2 Market size analysis, By Distribution Channel, 2020-2027
8.2.6.3 Market size analysis, By Formula Type, 2020-2027
8.2.7 Research Dive Exclusive Insights
8.2.7.1 Market attractiveness
8.2.7.2 Competition heatmap
8.3 Asia-Pacific
8.3.1 China
8.3.1.1 Market size analysis, By Application, 2020-2027
8.3.1.2 Market size analysis, By Distribution Channel, 2020-2027
8.3.1.3 Market size analysis, By Formula Type, 2020-2027
8.3.2 Japan
8.3.2.1 Market size analysis, By Application, 2020-2027
8.3.2.2 Market size analysis, By Distribution Channel, 2020-2027
8.3.2.3 Market size analysis, By Formula Type, 2020-2027
8.3.3 India
8.3.3.1 Market size analysis, By Application, 2020-2027
8.3.3.2 Market size analysis, By Distribution Channel, 2020-2027
8.3.3.3 Market size analysis, By Formula Type, 2020-2027
8.3.4 Australia
8.3.4.1 Market size analysis, By Application, 2020-2027
8.3.4.2 Market size analysis, By Distribution Channel, 2020-2027
8.3.4.3 Market size analysis, By Formula Type, 2020-2027
8.3.5 South Korea
8.3.5.1 Market size analysis, By Application, 2020-2027
8.3.5.2 Market size analysis, By Distribution Channel, 2020-2027
8.3.5.3 Market size analysis, By Formula Type, 2020-2027
8.3.6 Rest of Asia-Pacific
8.3.6.1 Market size analysis, By Application, 2020-2027
8.3.6.2 Market size analysis, By Distribution Channel, 2020-2027
8.3.6.3 Market size analysis, By Formula Type, 2020-2027
8.3.7 Research Dive Exclusive Insights
8.3.7.1 Market attractiveness
8.3.7.2 Competition heatmap
8.4 LAMEA
8.4.1 Brazil
8.4.1.1 Market size analysis, By Application, 2020-2027
8.4.1.2 Market size analysis, By Distribution Channel, 2020-2027
8.4.1.3 Market size analysis, By Formula Type, 2020-2027
8.4.2 Saudi Arabia
8.4.2.1 Market size analysis, By Application, 2020-2027
8.4.2.2 Market size analysis, By Distribution Channel, 2020-2027
8.4.2.3 Market size analysis, By Formula Type, 2020-2027
8.4.3 UAE
8.4.3.1 Market size analysis, By Application, 2020-2027
8.4.3.2 Market size analysis, By Distribution Channel, 2020-2027
8.4.3.3 Market size analysis, By Formula Type, 2020-2027
8.4.4 South Africa
8.4.4.1 Market size analysis, By Application, 2020-2027
8.4.4.2 Market size analysis, By Distribution Channel, 2020-2027
8.4.4.3 Market size analysis, By Formula Type, 2020-2027
8.4.5 Rest of LAMEA
8.4.5.1 Market size analysis, By Application, 2020-2027
8.4.5.2 Market size analysis, By Distribution Channel, 2020-2027
8.4.5.3 Market size analysis, By Formula Type, 2020-2027
8.4.6 Research Dive Exclusive Insights
8.4.6.1 Market attractiveness
8.4.6.2 Competition heatmap
9. Competitive Landscape
9.1 Top winning strategies, 2020-2027
9.1.1 By strategy
9.1.2 By year
9.2 Strategic overview
9.3 Market share analysis, 2020-2027
10. Company Profiles
10.1 Thermo Fisher Scientific, Inc.
10.1.1 Overview
10.1.2 Business segments
10.1.3 Product portfolio
10.1.4 Financial performance
10.1.5 Recent developments
10.1.6 SWOT analysis
10.2 Merck KGaA
10.2.1 Overview
10.2.2 Business segments
10.2.3 Product portfolio
10.2.4 Financial performance
10.2.5 Recent developments
10.2.6 SWOT analysis
10.3 Lonza
10.3.1 Overview
10.3.2 Business segments
10.3.3 Product portfolio
10.3.4 Financial performance
10.3.5 Recent developments
10.3.6 SWOT analysis
10.4 Cell Biologics, Inc.
10.4.1 Overview
10.4.2 Business segments
10.4.3 Product portfolio
10.4.4 Financial performance
10.4.5 Recent developments
10.4.6 SWOT analysis
10.5 PromoCell GmbH
10.5.1 Overview
10.5.2 Business segments
10.5.3 Product portfolio
10.5.4 Financial performance
10.5.5 Recent developments
10.5.6 SWOT analysis
10.6 HemaCare Corporation
10.6.1 Overview
10.6.2 Business segments
10.6.3 Product portfolio
10.6.4 Financial performance
10.6.5 Recent developments
10.6.6 SWOT analysis
10.7 ZenBio, Inc.
10.7.1 Overview
10.7.2 Business segments
10.7.3 Product portfolio
10.7.4 Financial performance
10.7.5 Recent developments
10.7.6 SWOT analysis
10.8 STEMCELL Technologies, Inc.
10.8.1 Overview
10.8.2 Business segments
10.8.3 Product portfolio
10.8.4 Financial performance
10.8.5 Recent developments
10.8.6 SWOT analysis
10.9 Corning Incorporated
10.9.1 Overview
10.9.2 Business segments
10.9.3 Product portfolio
10.9.4 Financial performance
10.9.5 Recent developments
10.9.6 SWOT analysis
10.10 AllCells
10.10.1 Overview
10.10.2 Business segments
10.10.3 Product portfolio
10.10.4 Financial performance
10.10.5 Recent developments
10.10.6 SWOT analysis
Personalize this research
- Triangulate with your own data
- Request your format and definition
- Get a deeper dive on a specific application, geography, customer or competitor
- + 1-888-961-4454 Toll - Free
- support@researchdive.com
